Obermatt
See Similar Stocks →

Flags

Financial distress

Tandem Diabetes

NMQ:TNDM · US8753722037
Health Care Equipment & SuppliesMedium

360

34
Profit price66
Owner Earnings Yield1
Dividend Yield1
Price/Sales76
EV / Gross Profit85
Price/Book11
Return on Capital31
Cash Return on Capital20
Return on Equity13
EBIT Margin29
Gross Profitability70
Accruals30
Owner Earnings Margin37
Sales growth18
Profit Growth6
Long-Term EPS Growth89
Reinvestment71
Price momentum61
Debt load13
Refinancing86
Debt Payback1
Liquidity34
Analyst ratings36
Opinion Changes50
Price Target Upside86
Market mood67
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Tandem Diabetes clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded2006
Employees1,909
Websitetandemdiabetes.com
ISINUS8753722037
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)D.J. US Medical Equipment
Themes
Biomedical EngineeringEndocrinologyMHealthDiabetesBiotechnologyHealth CareMedical Device

Description

Tandem Diabetes Care, Inc. (Tandem) operates as a global insulin delivery and diabetes technology company. The company engages in the design, development, and commercialization of advanced solutions that reduce the burden of diabetes management. The…

Analysis

Middle-of-the-road

Tandem Diabetes Care, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 8/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
55
2023202420252026

All-time high

55

Jun 2026

All-time low

9

Jan 2024

Average rank

32

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
76
46
56
36
Price/Earnings
97
46
46
15
Price/Book
11
23
39
27
Dividend Yield
1
1
1
1
Value (overall)
63
37
45
17

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Tandem Diabetes with its peers
ServiceTitan
NSQ:TTAN
39
CountryUSA
IndustrySoftware
SizeLarge
Full Stock Analysis →
MongoDB
NMQ:MDB
28
CountryUSA
IndustryIT Services
SizeLarge
Full Stock Analysis →
Box
NYQ:BOX
60
CountryUSA
IndustrySoftware
SizeLarge
Full Stock Analysis →
Backblaze
NMQ:BLZE
34
CountryUSA
IndustryIT Services
SizeSmall
Full Stock Analysis →
Snap
NYQ:SNAP
21
CountryUSA
IndustryInteractive Media & Services
SizeLarge
Full Stock Analysis →
Five9
NMQ:FIVN
85
CountryUSA
IndustrySoftware
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →